Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 6,990 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Carcinoma Clear all
Recruiting Phase 2 Interventional

Scalp Cooling in MBC

NCT04986579
View directory record Official record
Conditions
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Interventions
Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan
Device · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 16, 2026, 6:53 AM EDT
Not listed Not applicable Interventional

Prevention of Capsular Contracture Using Trental and Vitamin E

NCT01082003
View directory record Official record
Conditions
Capsular Contractures
Interventions
Trental
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Facilitating Oncology Patient-Clinician Communication Via E-health Innovations

NCT03442127
View directory record Official record
Conditions
Breast Cancer
Interventions
CaringGuidance™ After Breast Cancer Diagnosis
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 16, 2026, 6:53 AM EDT
Recruiting Phase 3 Interventional

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

NCT03418961
View directory record Official record
Conditions
Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Carvedilol, Laboratory Biomarker Analysis, Patient Observation
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
577
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

NCT00073073
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Calcium carbonate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Georgetown University
Other
Eligibility
Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

NCT00319254
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Duarte, California • Santa Monica, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women

NCT06635005
View directory record Official record
Conditions
Feasibility Pilot Study, Compliance
Interventions
Biospecimen Collection, Dietary Intervention, Medical Device Usage and Evaluation, Motivational Interviewing, Nutritional Assessment, Questionnaire Administration
Procedure · Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

NCT00232505
View directory record Official record
Conditions
Breast Cancer
Interventions
cetuximab, carboplatin
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

NCT02278120
View directory record Official record
Conditions
Advanced Metastatic Breast Cancer
Interventions
Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
35
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 16, 2026, 6:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
22
States / cities
Birmingham, Alabama • Buena, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 16, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

NCT06123988
View directory record Official record
Conditions
HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions
Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Phoenix, Arizona • Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 16, 2026, 6:53 AM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 16, 2026, 6:53 AM EDT
Recruiting Phase 1 Interventional

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

NCT05304962
View directory record Official record
Conditions
Breast Cancer
Interventions
RGT-419B, RGT-419B in combination with hormonal therapy
Drug
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral and Psychological Impact of Returning Breast Density Results to Latinas

NCT02910986
View directory record Official record
Conditions
Breast Cancer
Interventions
Written educational brochure, Promotora interaction
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
1,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 16, 2026, 6:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT04448886
View directory record Official record
Conditions
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab Govitecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Results available

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

NCT00452673
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Dasatinib, Capecitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Memory and Attention Adaptation Training-Geriatrics (MAAT-G)

NCT04230941
View directory record Official record
Conditions
Cancer-related Problem/Condition, Cognitive Impairment
Interventions
MAAT-G
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nipple Aspirate Fluid in Detecting Breast Cancer

NCT03715959
View directory record Official record
Conditions
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, Healthy Subject, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Luminal A Breast Carcinoma, Luminal B Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Aspiration of Breast, Biospecimen Collection
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Early Phase 1 Interventional

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

NCT03411070
View directory record Official record
Conditions
Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Implanted Medical Device, Therapeutic Conventional Surgery
Device · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Hula, a Physical Activity Intervention for Female-Cancer Survivors

NCT02351479
View directory record Official record
Conditions
Physical Activity, Breast Cancer, Cervical Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Hula
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
21 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Results available

Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients

NCT00317603
View directory record Official record
Conditions
Breast Cancer
Interventions
Autologous, Lethally Irradiated Breast Cancer Cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

NCT03018080
View directory record Official record
Conditions
Breast - Female, Male Breast Cancer
Interventions
Pembrolizumab, Paclitaxel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 16, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

Irofulven in Treating Patients With Metastatic Breast Cancer

NCT00003796
View directory record Official record
Conditions
Breast Cancer
Interventions
irofulven
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 16, 2026, 6:53 AM EDT
Completed No phase listed Observational

Registry of Mastectomy for Breast Cancer Risk Reduction

NCT00555503
View directory record Official record
Conditions
Quality of Life, Mastectomy, Breast Neoplasms, Genetic Predisposition to Disease, Adjustment Disorder
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 16, 2026, 6:53 AM EDT